Cortendo Ab (CRTOF) 1.1800 $CRTOF
Cortendo and Antisense Therapeutics signs exclusive licensing agreement for ATL1103 for acromegaly
M2 - Fri May 15, 5:56AM CDT
Cortendo AB (NOTC-A:CORT) (OTC:CRTOF), a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited (ASX:ANP), an Australian biopharmaceutical drug discovery and development company, announced on Thursday the entering into an exclusive license agreement that provides Cortendo with development and commercialisation rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
CORT: 5.75 (+0.01)
Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing
Business Wire - Fri May 15, 1:41AM CDT
--Cortendo Expands Investor Base Through New Private Placement
Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Business Wire - Thu May 14, 6:53PM CDT
Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
Cortendo AB Joins National Organization for Rare Disorders (NORD)(R) Corporate Council
Business Wire - Wed Apr 08, 8:12AM CDT
Regulatory News:
Cortendo AB Joins National Organization for Rare Disorders (NORD)® Corporate Council
PR Newswire - Wed Apr 08, 8:05AM CDT
Cortendo AB (publ) [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and the National Organization for Rare Disorders (NORD)®, a leading, independent nonprofit organization committed to the identification, treatment and cure of rare diseases, today announced that Cortendo has joined NORD's Corporate Council.
Cortendo AB names A. Brian Davis as CFO and Stephen Long as chief legal officer
M2 - Tue Mar 24, 6:43AM CDT
Biopharmaceutical company Cortendo AB (NOTC-A:CORT) announced on Monday that it has appointed A. Brian Davis as chief financial officer (CFO) and Stephen Long to the position of chief legal officer.
CORT: 5.75 (+0.01)
Cortendo AB Announces Appointments of A. Brian Davis as Chief Financial Officer and Stephen Long as Chief Legal Officer
Business Wire - Mon Mar 23, 7:15AM CDT
Regulatory News:
Cortendo AB Names John H. Johnson as Chairman and Appoints Richard Kollender as Director
Business Wire - Wed Mar 18, 7:08AM CDT
Regulatory News:
Cortendo announces new board members at Extraordinary General Meeting
M2 - Wed Mar 18, 3:20AM CDT
Cortendo AB (NOTC-A:CORT), a biopharmaceutical company focused on orphan endocrine disorders, announced on Tuesday that at the Extraordinary General Meeting held in Goteborg, John H. Johnson was elected, for the period until the end of the next annual general meeting, as new chairman of the board of directors.
CORT: 5.75 (+0.01)
Cortendo AB: Interim Report for the Fourth Quarter and Full Year 2014
Business Wire - Wed Mar 11, 10:04AM CDT
Regulatory News:
Cortendo Reports Results and Activities for the Fourth Quarter and Full Year 2014
Business Wire - Wed Mar 11, 9:29AM CDT
Cortendo AB:
Cortendo Completes $26.4m in Private Placement from Leading U.S. and EU Investors
Business Wire - Wed Feb 11, 10:36AM CST
Regulatory News:
Cortendo's resolutions on new share issues at Extraordinary General Meeting approved
M2 - Wed Feb 04, 5:28AM CST
Cortendo AB (NOTC-A:CORT)(OTC:CRTOF), a biopharmaceutical company focused on orphan endocrine disorders, on Tuesday reported the holding of an Extraordinary General Meeting in Goteborg.
CORT: 5.75 (+0.01)
Cortendo AB: Cortendo to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Mon Feb 02, 7:17AM CST
Regulatory News:
Cortendo AB: COR-003 Phase 3 Study Protocol to Be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
Business Wire - Thu Jan 29, 9:33AM CST
Regulatory News:
COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
Business Wire - Thu Jan 29, 7:03AM CST
Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing's syndrome at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo March 5-8 in San Diego, CA. This abstract will also be published in the April issue of Endocrine Reviews.
Cortendo AB: The Journal Diabetes Publishes Pre-clinical Data on Cortendo's Novel Diabetes Treatment, BP-2001
Business Wire - Wed Jan 28, 7:22AM CST
Regulatory News:
Cortendo reports sale of shares
M2 - Wed Jan 28, 6:08AM CST
Biopharmaceutical company Cortendo AB (OTC:CRTOF) announced on Tuesday that board members H. Joseph Reiser and Ernest Eichenberg III and Theodore R. Koziol, a consultant, have entered into agreement with a US institutional investor to sell 200,000, 150,000 and 150,000 shares in Cortendo, respectively, at a price of NOK6.10 per share.
Cortendo AB Raises up to $27.5M in Additional Private Placement with Leading U.S. and EU Healthcare Investors
Business Wire - Tue Jan 13, 8:09AM CST
Regulatory News:
Cortendo and Antisense Therapeutics signs exclusive licensing agreement for ATL1103 for acromegaly
M2 - Fri May 15, 5:56AM CDT
Cortendo AB (NOTC-A:CORT) (OTC:CRTOF), a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited (ASX:ANP), an Australian biopharmaceutical drug discovery and development company, announced on Thursday the entering into an exclusive license agreement that provides Cortendo with development and commercialisation rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
CORT: 5.75 (+0.01)
Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing
Business Wire - Fri May 15, 1:41AM CDT
--Cortendo Expands Investor Base Through New Private Placement
Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Business Wire - Thu May 14, 6:53PM CDT
Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
Cortendo AB Joins National Organization for Rare Disorders (NORD)(R) Corporate Council
Business Wire - Wed Apr 08, 8:12AM CDT
Regulatory News:
Cortendo AB Joins National Organization for Rare Disorders (NORD)® Corporate Council
PR Newswire - Wed Apr 08, 8:05AM CDT
Cortendo AB (publ) [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and the National Organization for Rare Disorders (NORD)®, a leading, independent nonprofit organization committed to the identification, treatment and cure of rare diseases, today announced that Cortendo has joined NORD's Corporate Council.
Cortendo AB names A. Brian Davis as CFO and Stephen Long as chief legal officer
M2 - Tue Mar 24, 6:43AM CDT
Biopharmaceutical company Cortendo AB (NOTC-A:CORT) announced on Monday that it has appointed A. Brian Davis as chief financial officer (CFO) and Stephen Long to the position of chief legal officer.
CORT: 5.75 (+0.01)
Cortendo AB Announces Appointments of A. Brian Davis as Chief Financial Officer and Stephen Long as Chief Legal Officer
Business Wire - Mon Mar 23, 7:15AM CDT
Regulatory News:
Cortendo AB Names John H. Johnson as Chairman and Appoints Richard Kollender as Director
Business Wire - Wed Mar 18, 7:08AM CDT
Regulatory News:
Cortendo announces new board members at Extraordinary General Meeting
M2 - Wed Mar 18, 3:20AM CDT
Cortendo AB (NOTC-A:CORT), a biopharmaceutical company focused on orphan endocrine disorders, announced on Tuesday that at the Extraordinary General Meeting held in Goteborg, John H. Johnson was elected, for the period until the end of the next annual general meeting, as new chairman of the board of directors.
CORT: 5.75 (+0.01)
Cortendo AB: Interim Report for the Fourth Quarter and Full Year 2014
Business Wire - Wed Mar 11, 10:04AM CDT
Regulatory News:
Cortendo Reports Results and Activities for the Fourth Quarter and Full Year 2014
Business Wire - Wed Mar 11, 9:29AM CDT
Cortendo AB:
Cortendo Completes $26.4m in Private Placement from Leading U.S. and EU Investors
Business Wire - Wed Feb 11, 10:36AM CST
Regulatory News:
Cortendo's resolutions on new share issues at Extraordinary General Meeting approved
M2 - Wed Feb 04, 5:28AM CST
Cortendo AB (NOTC-A:CORT)(OTC:CRTOF), a biopharmaceutical company focused on orphan endocrine disorders, on Tuesday reported the holding of an Extraordinary General Meeting in Goteborg.
CORT: 5.75 (+0.01)
Cortendo AB: Cortendo to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Mon Feb 02, 7:17AM CST
Regulatory News:
Cortendo AB: COR-003 Phase 3 Study Protocol to Be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
Business Wire - Thu Jan 29, 9:33AM CST
Regulatory News:
COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
Business Wire - Thu Jan 29, 7:03AM CST
Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing's syndrome at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo March 5-8 in San Diego, CA. This abstract will also be published in the April issue of Endocrine Reviews.
Cortendo AB: The Journal Diabetes Publishes Pre-clinical Data on Cortendo's Novel Diabetes Treatment, BP-2001
Business Wire - Wed Jan 28, 7:22AM CST
Regulatory News:
Cortendo reports sale of shares
M2 - Wed Jan 28, 6:08AM CST
Biopharmaceutical company Cortendo AB (OTC:CRTOF) announced on Tuesday that board members H. Joseph Reiser and Ernest Eichenberg III and Theodore R. Koziol, a consultant, have entered into agreement with a US institutional investor to sell 200,000, 150,000 and 150,000 shares in Cortendo, respectively, at a price of NOK6.10 per share.
Cortendo AB Raises up to $27.5M in Additional Private Placement with Leading U.S. and EU Healthcare Investors
Business Wire - Tue Jan 13, 8:09AM CST
Regulatory News:
